Dyslipidemias
📧 Sign up to get email alerts when something new happens for Dyslipidemias.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-09-11Clinical Trial Update: Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA) [NA]
The HIIT&PUFA trial examining high-intensity interval training plus omega-3 fatty acid supplementation for obesity-related inflammation and …
-
CLINICAL_TRIALS withdrawal · 2025-07-14Clinical Trial Update: Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia [Phase 2]
A Phase 2 clinical trial of vildagliptin for treating antipsychotic-induced dyslipidemia in schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-24Clinical Trial Update: Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A [Phase 3]
A Phase 3 trial evaluating adding DKP21102_B to DKP21102_A for dyslipidemias was withdrawn and will not proceed.
-
CLINICAL_TRIALS withdrawal · 2019-06-21Clinical Trial Update: Fixed Combination for Lipid and Blood Pressure Control [Phase 4]
A Phase 4 trial evaluating a fixed-dose combination for lipid and blood pressure control was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2019-06-13Clinical Trial Update: Early Alirocumab to Reduce LDL-C in Myocardial Infarction [Phase 4]
Phase 4 trial investigating alirocumab to reduce LDL-C in patients with myocardial infarction was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2013-05-16EMA Withdrawn: Trevaclyn (laropiprant;nicotinic acid) — Merck Sharp Dohme Ltd
Trevaclyn (laropiprant; nicotinic acid) has been withdrawn from the market by Merck Sharp & Dohme Ltd for dyslipidemias.
-
EMA withdrawal · 2013-05-16EMA Withdrawn: Pelzont (laropiprant;nicotinic acid) — Merck Sharp Dohme Ltd
EMA announced the withdrawal of Pelzont (laropiprant and nicotinic acid) from the market for dyslipidemias.
-
EMA withdrawal · 2013-05-16EMA Withdrawn: Tredaptive (laropiprant;nicotinic acid) — Merck Sharp Dohme Ltd.
EMA has withdrawn Tredaptive (laropiprant and nicotinic acid) from the market, in the dyslipidemias therapeutic area.